Sign In
Buy BDTX
$1.61
-0.0500 (-3.01%)
At Close: Jun 22, 2026
Black Diamond (BDTX) is on the Move, Here's Why the Trend Could be Sustainable
09:51am, Monday, 29'th Apr 2024
Black Diamond (BDTX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Does Black Diamond (BDTX) Have the Potential to Rally 152.96% as Wall Street Analysts Expect?
10:56am, Thursday, 25'th Apr 2024
The mean of analysts' price targets for Black Diamond (BDTX) points to a 153% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ana
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
04:05pm, Wednesday, 24'th Apr 2024
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic
Black Diamond (BDTX) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Monday, 15'th Apr 2024
Black Diamond (BDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Black Diamond Therapeutics Announces Changes to Board of Directors
08:00am, Thursday, 11'th Apr 2024
CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic
Wall Street Analysts Predict a 129.25% Upside in Black Diamond (BDTX): Here's What You Should Know
10:56am, Monday, 08'th Apr 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 129.3% in Black Diamond (BDTX). While the effectiveness of this highly sought-after metric is questionable, the
Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 03'rd Apr 2024
CAMBRIDGE, Mass. and NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families
How Much Upside is Left in Black Diamond Therapeutics (BDTX)? Wall Street Analysts Think 95.93%
10:55am, Friday, 22'nd Mar 2024
The mean of analysts' price targets for Black Diamond Therapeutics (BDTX) points to a 95.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agree
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
08:00am, Tuesday, 12'th Mar 2024
CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company focused on the development of MasterKey therapies to treat patie
Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
04:30pm, Tuesday, 05'th Mar 2024
Abstract accepted for oral presentation on the evolving EGFR mutational landscape in NSCLC and MasterKey profile of BDTX-1535 addressing a broad spectrum of mutations Abstract accepted for oral presen
Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
08:00am, Wednesday, 28'th Feb 2024
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic
Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM
05:21pm, Friday, 12'th Jan 2024
Black Diamond Therapeutics is a precision oncology company targeting genetically defined cancers with its Masterkey approach. Besides NSCLC, BDTX also produced positive early data in recurrent GBM, a
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
08:00am, Thursday, 04'th Jan 2024
FDA feedback on BDTX-1535 enables initiation of Phase 2 cohort in first-line treatment of non-classical EGFR mutant NSCLC
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM
07:00am, Wednesday, 13'th Dec 2023
Initial results show promising clinical activity in heavily pretreated patients 22 patients evaluable for efficacy: 3 patients on therapy longer than 10 months, 1 patient longer than 6 months, and 5 p
